WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2018028841) SOLID PHARMACEUTICAL COMPOSITION OF ABACAVIR, LAMIVUDINE, AND EFAVIRENZ
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.:    WO/2018/028841    International Application No.:    PCT/EP2017/053326
Publication Date: 15.02.2018 International Filing Date: 14.02.2017
IPC:
A61K 9/20 (2006.01), A61K 9/28 (2006.01), A61K 31/52 (2006.01), A61K 31/536 (2006.01), A61K 31/7068 (2006.01)
Applicants: SANDOZ AG [CH/CH]; Lichtstrasse 35 4056 Basel (CH)
Inventors: JANKOVIC, Biljana; (SI).
ALEKSOVSKI, Aleksandar; (SI).
BERGINC, Katja; (SI).
JOKSIMOVIC, Tatjana; (SI)
Agent: KLUSCHANZOFF, Harald; (DE).
HODZAR, Damjan; (SI)
Priority Data:
PCT/EP2016/069261 12.08.2016 EP
Title (EN) SOLID PHARMACEUTICAL COMPOSITION OF ABACAVIR, LAMIVUDINE, AND EFAVIRENZ
(FR) COMPOSÉ PHARMACEUTIQUE SOLIDE D'ABACAVIR, DE LAMIVUDINE ET D'ÉFAVIRENZ.
Abstract: front page image
(EN)The present invention describes a fixed dose oral formulation of a triple HIV antiviral combination of abacavir (notably abacavir sulphate), lamivudine and efavirenz, useful in the treatment of HIV infections in the form of a multi-layer tablet, preferably a bi-layer tablet. The described formulations combine a number of valuable use attributes, including reduction of mouth burning effect caused by efavirenz as well as for providing of palatable formulations for high drug loaded system that is important for a triple fixed dose combination, without however to the detriment of dissolution properties for each active ingredient.
(FR)L'invention décrit une formule orale, à dose fixe, d'une triple combinaison antivirale d'abacavir contre le VIH (notamment le sulfate d'abacavir), de lamivudine et d'éfavirenz. Les formules décrites combinent un certain nombre d'avantages comprenant la réduction de l'effet de brûlure de la bouche provoqué par l'éfavirenz, un meilleur goût pour les formules très concentrées, ce qui est important pour une triple combinaison à dose fixe, sans cependant nuire aux propriétés de dissolution de chaque ingrédient actif.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)